A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer

NCT04999605 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped Too low inclusion rate

Conditions

Ovarian Neoplasms
Recurrent Ovarian Carcinoma
Relapsed Ovarian Cancer
Ovarian Cancer

Interventions

DRUG: AK112 low dose
DRUG: AK112 medium dose
DRUG: AK112 high dose

Sponsor

Akeso